stockrowDexCom, Inc.
DXCM Healthcare Medical Devices
DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.
- Revenue
- +11.2%
- EPS
- 0.00%
- Free cash flow
- −52.9%
- Total debt
- +0.31%
Quarter to September 2026, against a year earlier
Follow DXCM
Alert me
DexCom, Inc. (DXCM) Return on assets
DexCom, Inc.'s return on assets over the twelve months to 30 September 2026 was 14.4%, up 1.4 percentage points from fiscal 2025 (13.0%). Over the past ten years it has ranged from −24.2% (fiscal 2015) to 16.4% (fiscal 2020); the current reading is higher than 91% of that period. That is above the Medical Devices industry median of −17.3% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 13.0% | 4.00 |
| FY2024 | 9.04% | (0.25) |
| FY2023 | 9.29% | 2.68 |
| FY2022 | 6.61% | 1.91 |
| FY2021 | 4.70% | (11.74) |
| FY2020 | 16.4% | 11.75 |
| FY2019 | 4.69% | 13.70 |
| FY2018 | −9.01% | (1.33) |
| FY2017 | −7.68% | 11.20 |
| FY2016 | −18.9% | 5.29 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| DXCM DexCom, Inc. | 14.4% |
| BSX Boston Scientific Corporation compare | 7.94% |
| STE STERIS plc compare | 7.83% |
| EW Edwards Lifesciences Corporation compare | 7.45% |
| GEHC GE HealthCare Technologies Inc. compare | 5.78% |
| PHG Koninklijke Philips N.V. compare | 3.49% |
| ZBH Zimmer Biomet Holdings, Inc. compare | 3.26% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| GKOS Glaukos Corporation compare | −17.2% |
| Medical Devices industry median | −17.3% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on DXCM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement